Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Review

IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma

Authors: Muhammad Saalim, Saleha Resham, Sobia Manzoor, Hassam Ahmad, Shahla Jaleel, Javed Ashraf, Muhammad Imran, Sidrah Naseem

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is a growing concern all over the world. With the number of patients rising exponentially with each passing day, HCC is a problem that needs immediate attention. Currently, available treatment strategies focus on controlling the damage after the development of HCC. The options available from chemo- and radio-embolization to surgical resection and transplantation are not efficacious as required due to the complex nature of the disease. Liver regeneration and tissue healing are the subject of great interest today. Interleukin-22 (IL-22) is a cytokine with the ability to regenerate and therefore reverse the injuries caused by a wide range of agents. IL-22 acts via STAT molecule and controls the activity of a wide variety of cell survival and proliferation genes. Experimental data has given a positive insight into the role of IL-22 in inhibition of viral and alcohol-induced hepatocellular carcinoma. A further insight into the nature of IL-22 and the factors that can be manipulated in controlling the activity of IL-22 can help to counter the menace caused by the devastating effects of HCC.
Literature
1.
2.
Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36(5):1206–13.CrossRefPubMed
3.
Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42(2):218–24.CrossRefPubMed
4.
5.
6.
Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22(33):5093–107.CrossRefPubMed
7.
Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436(7053):933–8.CrossRefPubMed
8.
Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006;25(27):3834–47.CrossRefPubMed
9.
Rehermann B. Hepatitis C, virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119(7):1745–54.CrossRefPubMedPubMedCentral
10.
Dumoutier L, Louahed J, Renauld J-C. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000;164(4):1814–9.CrossRefPubMed
11.
Radaeva S, Sun R, Pan H, Hong F, Gao B, Interleukin 22. (IL‐22) plays a protective role in T cell‐mediated murine hepatitis: IL‐22 is a survival factor for hepatocytes via STAT3 activation. Hepatology. 2004;39(5):1332–42.CrossRefPubMed
12.
Dumoutier L, de Meester C, Tavernier J, Renauld J-C. New activation modus of STAT3 a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem. 2009;284(39):26377–84.CrossRefPubMedPubMedCentral
13.
Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281–3.CrossRefPubMed
14.
Bromberg J, Darnell Jr JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19(21):2468–73.CrossRefPubMed
15.
Yoshida T, Hanada T, Tokuhisa T, Kosai K-I, Sata M, Kohara M. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med. 2002;196(5):641–53.CrossRefPubMedPubMedCentral
16.
Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol. 2005;2(2):92–100.PubMed
17.
18.
Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011;7(5):536.CrossRefPubMedPubMedCentral
19.
Nagem RAP, Colau D, Dumoutier L, Renauld J-C, Ogata C, Polikarpov I. Crystal structure of recombinant human interleukin-22. Structure. 2002;10(8):1051–62.CrossRefPubMed
20.
de Oliveira NM, Ferreira Jr JR, Colau D, Fischer H, Nascimento AS, Craievich AF, et al. Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains. Biophys J. 2008;94(5):1754–65.CrossRef
21.
Foster RG, Golden-Mason L, Rutebemberwa A, Rosen HR. Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci. 2012;57(2):381–9.CrossRefPubMed
22.
Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S et al. Serum levels of interleukin‐22 and hepatitis B core‐related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatology Research. 2014.
23.
Dambacher J, Beigel F, Zitzmann K, Heeg MH, Göke B, Diepolder HM, et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine. 2008;41(3):209–16.CrossRefPubMed
24.
Ki SH, Park O, Zheng M, Morales‐Ibanez O, Kolls JK, Bataller R, et al. Interleukin‐22 treatment ameliorates alcoholic liver injury in a murine model of chronic‐binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010;52(4):1291–300.CrossRefPubMedPubMedCentral
25.
Støy S, Sandahl TD, Dige AK, Agnholt J, Rasmussen TK, Grønbæk H, et al. Highest frequencies of interleukin-22-producing T helper cells in alcoholic hepatitis patients with a favourable short-term course. PLoS One. 2013;8(1), e55101.CrossRefPubMedPubMedCentral
26.
Ashour TH. Therapy with interleukin-22 alleviates hepatic injury and hemostasis dysregulation in rat model of acute liver failure. Advances in hematology. 2014; 2014.
27.
28.
Gurtsevitch V. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochem Mosc. 2008;73(5):504–13.CrossRef
29.
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674–87.CrossRefPubMed
30.
Kitaoka S, Shiota G, Kawasaki H. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepato-Gastroenterology. 2002;50(53):1569–74.
31.
Huang Y, Hwang S, Chan C, Wu J, Chao Y, Chang F, et al. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua yi xue za zhi = Chinese medical journal. Free China ed. 1999;62(6):327–33.
32.
Sato T, Asanuma Y, Masaki Y, Sato Y, Hatakeyama Y, Kusano T, et al. Changes in tumor necrosis factor-a and interleukin-1 beta production following liver surgery on cirrhotic patients. Hepato-Gastroenterology. 1995;43(11):1148–53.
33.
Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld J-C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line pathways that are shared with and distinct from IL-10. J Biol Chem. 2002;277(37):33676–82.CrossRefPubMed
34.
Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005;174(6):3695–702.CrossRefPubMed
35.
Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36(5):1309–23.CrossRefPubMed
36.
Pan H, Hong F, Radaeva S, Gao B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol. 2004;1(1):43–9.PubMed
37.
Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005;129(3):969–84.CrossRefPubMed
38.
Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity. 2007;27(4):647–59.CrossRefPubMedPubMedCentral
39.
Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, et al. In vivo consequences of liver‐specific interleukin‐22 expression in mice: implications for human liver disease progression. Hepatology. 2011;54(1):252–61.CrossRefPubMedPubMedCentral
40.
Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, et al. Interleukin‐22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012;56(3):1150–9.CrossRefPubMedPubMedCentral
41.
Kong X, Feng D, Mathews S, Gao B. Hepatoprotective and anti‐fibrotic functions of interleukin‐22: therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol. 2013;28(S1):56–60.CrossRefPubMedPubMedCentral
42.
W-w X, M-j Z, Liu S, Xu T, Gao J, Wang J-x, et al. Hepatoprotective effects of IL-22 on fulminant hepatic failure induced by d-galactosamine and lipopolysaccharide in mice. Cytokine. 2011;56(2):174–9.CrossRef
43.
Liang SC, Nickerson-Nutter C, Pittman DD, Carrier Y, Goodwin DG, Shields KM, et al. IL-22 induces an acute-phase response. J Immunol. 2010;185(9):5531–8.CrossRefPubMed
44.
Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem. 2006;281(20):14111–8.CrossRefPubMed
45.
Zhang Y, Ji H, Liu Y, Shen X, Gao F, Fong C et al., editors. The immunomodulatory role of IL-22 in mouse liver ischemia and reperfusion injury (IRI): enhancement of autophagy by STAT3-c-myc signaling. American Journal of Transplantation; 2013: Wiley-Blackwell 111 River ST, Hoboken 07030-5774, NJ USA.
46.
Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, et al. Pathological functions of interleukin‐22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology. 2014;59(4):1331–42.CrossRefPubMedPubMedCentral
47.
Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology. 2011;141(5):1897–906.CrossRefPubMedPubMedCentral
48.
Chestovich PJ, Uchida Y, Chang W, Ajalat M, Lassman C, Sabat R, et al. IL-22: implications for liver ischemia/reperfusion injury. Transplantation. 2012;93(5):485.CrossRefPubMedPubMedCentral
49.
Feng D, Wang Y, Wang H, Weng H, Kong X, Martin-Murphy BV, et al. Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. J Immunol. 2014;193(5):2512–8.CrossRefPubMedPubMedCentral
50.
Zhang Z, Zhao J, Fu Y, Wang F-S. Increased IL-22-producing cells contribute to liver fibrosis through promoting Th17 migration in chronic HBV patients (P3363). The Journal of Immunology. 2013;190 (meeting abstracts 1):202.4.
51.
Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, et al. Interleukin‐22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011;54(3):900–9.CrossRefPubMed
Metadata
Title
IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma
Authors
Muhammad Saalim
Saleha Resham
Sobia Manzoor
Hassam Ahmad
Shahla Jaleel
Javed Ashraf
Muhammad Imran
Sidrah Naseem
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4294-1

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma

Research Article

Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models

Original Article

Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma

Original Article

The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor

Original Article

Five miRNAs considered as molecular targets for predicting neuroglioma

Review

GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits